الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 195 |  |  |
| | | from | 195 | | |
Abstract
Cancer survivors are increasing nowadays however with an increased incidence of cardiovascular complications mainly due to the cardiotoxic effect of cancer chemotherapy. Such cardiotoxic changes may adversely affect the clinical condition of cancer survivors. Therefore, monitoring cancer patients using cardiac imaging has been increasingly implemented in the cardiooncology field, which may provide early diagnosis and prevention of chemotherapy-related cardiovascular complications through allowing early use of different cardioprotective measures.
This study was designed to assess the role of CMR in the identification of patients at risk based on the early detection of cardiotoxic changes as well as to define parameters which could predict late cardiac changes after 3 months follow up of patients treated with cancer chemotherapy. To our knowledge, this is the first prospective study to assess the use of CMR in the detection of cardiotoxicity under BRAF and MEKi as well as Carfilzomib treatment.
In this prospective longitudinal observational study, cancer patients who were scheduled to undergo treatment with cardiotoxic cancer treatments have been recruited and performed three CMR examinations; before onset of therapy (baseline) as well as 3-6 days and 3 months thereafter. The CMR parameters included LV/RV standard morphological and functional parameters as well as tissue characterization parameters (LV global native T1 and T2 Mapping) and LV/RV deformation parameters (GLS, GCS and LV percentage of healthy myocardium). Serological cardiac biomarkers and echocardiography were also obtained